Cyna Pharma: Reaping the rewards of perseverance (A)
The A case tells the story of Anthony Giovinazzo’s entrepreneurial journey with Cyna Pharma, which he built from the ground up. Cyna Pharma was a Canada-based specialty pharmaceutical company that was at the point of conducting Phase 3 clinical trials in 2016 for its main product: APL-130277 – a novel delivery mechanism for an existing drug called apomorphine, used for on-demand treatment of the debilitating off-episodes (freezing) associated with Parkinson’s disease (PD). The case provides an overview of Anthony’s unique background, the off-episodes associated with Parkinson’s disease, the specialty biopharma sector, the funding rounds to get to Phase 3 clinical trials and the brushes with disaster along the way. It also describes the steps to getting listed on the NASDAQ and the benefits of doing so. After an earlier offer to acquire the company the case ends with a similar offer from Sundown Pharma a year later. As the case comes to a close, Anthony is faced with a moment of truth: Should he move forward with launching the product himself, or should he license his product with a partner or agree to an outright acquisition by a big pharma company?
- Managing growth in a biopharma company
- Leadership in a pharma company, from start-up to listed firm and trade sale
- Developing resilience in a firm – managing risk
Cyna Pharma (Disguised), Healthcare, Biopharmaceuticals
2002–2016
Cranfield University
Wharley End Beds MK43 0JR, UK
Tel +44 (0)1234 750903
Email [email protected]
Harvard Business School Publishing
60 Harvard Way, Boston MA 02163, USA
Tel (800) 545-7685 Tel (617)-783-7600
Fax (617) 783-7666
Email [email protected]
NUCB Business School
1-3-1 Nishiki Naka
Nagoya Aichi, Japan 460-0003
Tel +81 52 20 38 111
Email [email protected]
IMD retains all proprietary interests in its case studies and notes. Without prior written permission, IMD cases and notes may not be reproduced, used, translated, included in books or other publications, distributed in any form or by any means, stored in a database or in other retrieval systems. For additional copyright information related to case studies, please contact Case Services.
Research Information & Knowledge Hub for additional information on IMD publications
- Cyna Pharma: Reaping the rewards of perseverance (A)
- Cyna Pharma: Reaping the rewards of perseverance (B)
- Cyna Pharma: Reaping the rewards of perseverance (A)
- Cyna Pharma: Reaping the rewards of perseverance (B)
Case reference: IMD-7-2316 ©2022
Research Information & Knowledge Hub for additional information on IMD publications
Case reference: IMD-7-2317 ©2022
Research Information & Knowledge Hub for additional information on IMD publications
The idea of an EU bond, a common safe asset, has been gaining attention lately, particularly following calls for its introduction this month by former Italian prime minister Mario Draghi.
In addition to traditional venture capital (VC), governmental VC and social impact VC investors have emerged as alternatives to fund entrepreneurial ventures, especially start-ups that incorporate social and/or environmental objectives into commer...
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
in I by IMD
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
in Finance Research Letters October 2024, vol. 68, 105987, https://doi.org/10.1016/j.frl.2024.105987
Research Information & Knowledge Hub for additional information on IMD publications
in I by IMD
Research Information & Knowledge Hub for additional information on IMD publications